Paper34130596
Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.
Pacheco MB and 3 others. Epigenetics, 2022. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Epigenetic Editing in Prostate Cancer: Challenges and Opportunities. Papers, record 34130596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34130596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Editing | Major topic |
| Prostatic Neoplasms | Major topic |
| CRISPR-Cas Systems | |
| Chromatin | |
| DNA Methylation | |
| Epigenesis, Genetic | |
| Humans | |
| Male |
Source PubMed
References253
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24108092 | Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. | Nat Biotechnol | 2013 | https://conductscience.org/library/papers/24108092 | PubMed |
| 2 | 32097843 | Novel approach to therapeutic targeting of castration-resistant prostate cancer. | Med Hypotheses | 2020 | https://conductscience.org/library/papers/32097843 | PubMed |
| 3 | 24793694 | A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer. | Mol Cell | 2014 | https://conductscience.org/library/papers/24793694 | PubMed |
| 4 | 26000489 | Integrative clinical genomics of advanced prostate cancer. | Cell | 2015 | https://conductscience.org/library/papers/26000489 | PubMed |
| 5 | 26025803 | Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. | Genome Res | 2015 | https://conductscience.org/library/papers/26025803 | PubMed |
| 6 | 23546521 | The future of epigenetic therapy in solid tumours--lessons from the past. | Nat Rev Clin Oncol | 2013 | https://conductscience.org/library/papers/23546521 | PubMed |
| 7 | 33414404 | Prostate apoptosis response-4 and tumor suppression: it's not just about apoptosis anymore. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/33414404 | PubMed |
| 8 | 19933107 | Breaking the code of DNA binding specificity of TAL-type III effectors. | Science | 2009 | https://conductscience.org/library/papers/19933107 | PubMed |
| 9 | 21764166 | Histone modification: cause or cog? | Trends Genet | 2011 | https://conductscience.org/library/papers/21764166 | PubMed |
| 10 | 28624514 | Bromodomain-containing proteins in prostate cancer. | Mol Cell Endocrinol | 2018 | https://conductscience.org/library/papers/28624514 | PubMed |
| 11 | 31901636 | Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. | iScience | 2020 | https://conductscience.org/library/papers/31901636 | PubMed |
| 12 | 27272384 | Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. | Nat Biotechnol | 2016 | https://conductscience.org/library/papers/27272384 | PubMed |
| 13 | 22120715 | Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. | Oncogene | 2012 | https://conductscience.org/library/papers/22120715 | PubMed |
| 14 | 23892898 | CRISPR RNA-guided activation of endogenous human genes. | Nat Methods | 2013 | https://conductscience.org/library/papers/23892898 | PubMed |
| 15 | 17962565 | A bacterial effector acts as a plant transcription factor and induces a cell size regulator. | Science | 2007 | https://conductscience.org/library/papers/17962565 | PubMed |
| 16 | 2443238 | Hypomethylation of DNA in pathological conditions of the human prostate. | Cancer Res | 1987 | https://conductscience.org/library/papers/2443238 | PubMed |
| 17 | 18507002 | DNA damage response in prostate cancer cells after high-intensity focused ultrasound (HIFU) treatment. | Anticancer Res | 2008 | https://conductscience.org/library/papers/18507002 | PubMed |
| 18 | 31053162 | Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner. | Epigenetics Chromatin | 2019 | https://conductscience.org/library/papers/31053162 | PubMed |
| 19 | 26066060 | Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing. | Sci Rep | 2015 | https://conductscience.org/library/papers/26066060 | PubMed |
| 20 | 30640437 | Precision Control of CRISPR-Cas9 Using Small Molecules and Light. | Biochemistry | 2019 | https://conductscience.org/library/papers/30640437 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40722714 | Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722714 | PubMed |
| 40694614 | Epigenetic alterations in prostate cancer: the role of chromatin remodeling. | Epigenomics | 2025 | https://conductscience.org/library/papers/40694614 | PubMed |
| 40600050 | Precision scalpels for the epigenome: next-gen editing tools in targeted therapies. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40600050 | PubMed |
| 39820138 | Prostate cancer epigenetics - from pathophysiology to clinical application. | Nat Rev Urol | 2025 | https://conductscience.org/library/papers/39820138 | PubMed |
| 38102645 | The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing. | Cell Commun Signal | 2023 | https://conductscience.org/library/papers/38102645 | PubMed |
| 37228649 | H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets. | Front Cell Dev Biol | 2023 | https://conductscience.org/library/papers/37228649 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34130596
GET https://conductscience.org/api/papers/v1/34130596/references?page=2